Filtered By:
Drug: Lipitor

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 101 results found since Jan 2013.

0200: N-Acetylcystein protects mitochondrial function of myoblasts against statin-induced apoptosis by triggering a mitohormesis mechanism
In conclusion, we demonstrated that NAC activates the mechanisms of mitochondrial biogenesis by increasing mitochondrial ROS production, allowing to increase the metabolic power as well as the cellular antioxidant systems The Activation of this mitohormesis phenomenon represents an interesting research field in order to protect the cells against oxidative stress. One week NAC pretreatment protects against Statins. Abstract 0200 – Figure
Source: Archives of Cardiovascular Diseases Supplements - October 12, 2014 Category: Cardiology Source Type: research

Red yeast rice and coenzyme Q10 as safe alternatives to surmount atorvastatin-induced myopathy in hyperlipidemic rats.
In conclusion, RYR and CoQ10 may offer alternatives to overcome atorvastatin-associated myopathy. PMID: 24896301 [PubMed - in process]
Source: Canadian Journal of Physiology and Pharmacology - June 1, 2014 Category: Drugs & Pharmacology Authors: Abdelbaset M, Safar MM, Mahmoud SS, Negm SA, Agha AM Tags: Can J Physiol Pharmacol Source Type: research

No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. Mol Biol Rep. 2014 Mar 26; Authors: Giannakopoulou E, Ragia G, Kolovou V, Tavridou A, Tselepis AD, Elisaf M, Kolovou G, Manolopoulos VG Abstract Interindividual variability exists in statin lipid-lowering response, partially attributed to genetic factors. Organic anion-transporting polypeptide 1B1 (OATP1B1) encoded by SLCO1B1 gene (solute carrier organic anion transporter family member 1B1) facilitates hepatic uptake of simvastatin and atorvastatin. SLCO1B1 polymorphisms are strongly...
Source: Molecular Biology Reports - March 26, 2014 Category: Molecular Biology Authors: Giannakopoulou E, Ragia G, Kolovou V, Tavridou A, Tselepis AD, Elisaf M, Kolovou G, Manolopoulos VG Tags: Mol Biol Rep Source Type: research

Myopathy after Switching from Brand to Generic Atorvastatin
Source: Journal of the American Geriatrics Society - December 12, 2013 Category: Geriatrics Authors: Omodele Awoniyi, Aidar R. Gosmanov Tags: Letters to the Editor Source Type: research

SLCO1B1 Polymorphisms and Statin-Induced Myopathy
Clinical scenario Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors which reduce the risk of coronary events and death by lowering blood concentrations of low density lipoprotein cholesterol (LDL-c).1,2,3,4 They are generally regarded as safe and well tolerated. However, some patients experience adverse muscle symptoms; these are mostly relatively mild but, in rare cases, severe muscle damage with renal failure (rhabdomyolysis) may occur (reviewed in 5,6). Recently, an autoimmune form of necrotising myositis has also been identified as a rare statin-associated myopathy (reviewed in 7). There ...
Source: PLOS Currents Evidence on Genomic Tests - December 4, 2013 Category: Genetics & Stem Cells Authors: Alison Stewart Source Type: research

Rhabdomyolysis in an elderly multitreated patient: Multiple drug interactions after statin withdrawal
We report rhabdomyolysis in an elderly patient, in multitreatment with different potentially myotoxic medications, taking place seven months after atorvastatin discontinuation. Affected by ischaemic heart disease, arterial hypertension and dementia-related behaviour disturbances, the patient was receiving angiotensin 2-receptor inhibitors, beta-blockers, vasodilators, diuretics, salycilates, allopurinol, proton pump inhibitors, antipsychotics and antidepressants. He had taken atorvastatin for 14years, with constantly normal creatine-kinase plasma levels. Two months after addition of the antianginal drug ranolazine, creatin...
Source: Journal of the Neurological Sciences - November 19, 2013 Category: Neurology Authors: Federica Ginanneschi, Nila Volpi, Fabio Giannini, Raffaele Rocchi, Donatella Donati, Margherita Aglianò, Paola Lorenzoni, Alessandro Rossi Tags: Short Communications Source Type: research

Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care Original Articles
Conclusions— Interindividual variability in statin exposure in patients is associated with uptake and efflux transporter polymorphisms. An algorithm incorporating genomic and clinical variables to avoid high atorvastatin and rosuvastatin levels is described; further study will determine whether this approach reduces incidence of statin myopathy.
Source: Circulation: Cardiovascular Genetics - August 20, 2013 Category: Cardiology Authors: DeGorter, M. K., Tirona, R. G., Schwarz, U. I., Choi, Y.-H., Dresser, G. K., Suskin, N., Myers, K., Zou, G., Iwuchukwu, O., Wei, W.-Q., Wilke, R. A., Hegele, R. A., Kim, R. B. Tags: Cardiovascular Pharmacology Original Articles Source Type: research

Effects of Aggressive Statin Therapy on Patients With Coronary Saphenous Vein Bypass Grafts: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
CONCLUSIONS: Compared with moderate statin therapy, long-term aggressive statin lowered the LDL-C level significantly, further decreased the atherosclerotic progression of SVG, reduced the risks of repeated myocardial infarction and coronary revascularization after CABG, and revealed similar patient compliance and statin-related adverse effects but slightly increased myopathy events and aminotransferase levels. PMID: 23932462 [PubMed - as supplied by publisher]
Source: Clinical Therapeutics - August 7, 2013 Category: Drugs & Pharmacology Authors: Kang S, Liu Y, Liu XB Tags: Clin Ther Source Type: research

Statin-Associated Polymyositis Following Omeprazole Treatment.
Abstract Statins are an extensively used class of drugs, and myopathy is an uncommon, but well-described side effect of statin therapy. Inflammatory myopathies, including polymyositis, dermatomyositis, and necrotizing autoimmune myopathy, are even rarer, but debilitating, side effects of statin therapy that are characterized by the persistence of symptoms even after discontinuation of the drug. It is important to differentiate statin-associated inflammatory myopathies from other self-limited myopathies, as the disease often requires multiple immunosuppressive therapies. Drug interactions increase the risk of stati...
Source: Clinical Medicine and Research - April 12, 2013 Category: Journals (General) Authors: Kanth R, Shah MS, Flores RM Tags: Clin Med Res Source Type: research

Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy.
CONCLUSIONS: Although areas of uncertainty remain, intermittent dosing (particularly with rosuvastatin and atorvastatin) in previously intolerant patients is a useful strategy to capitalize on the benefits of this therapy. Larger scale randomized trials are necessary to more clearly define the role of this strategy and the optimal choice of regimen. PMID: 23482733 [PubMed - in process]
Source: The Annals of Pharmacotherapy - March 1, 2013 Category: Drugs & Pharmacology Authors: Keating AJ, Campbell KB, Guyton JR Tags: Ann Pharmacother Source Type: research

No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy
Scandinavian Cardiovascular Journal, Volume 0, Issue 0, Page 1-8, Early Online.
Source: Scandinavian Cardiovascular Journal - January 11, 2013 Category: Cardiology Tags: article Source Type: research